Eyenovia Reports Third Quarter 2024 Financial Results and Provides Corporate Update Advanced Phase 3 CHAPERONE study of MicroPine as a treatment of pediatric progressive myopia with preparations for interim analysis this

Eyenovia Reports Third Quarter 2024 Financial

Results and Provides Corporate Update

Advanced Phase 3 CHAPERONE study of MicroPine

as a treatment of pediatric progressive myopia with preparations for interim analysis this quarter

Commenced the manufacture of registration batches

of Mydcombi in its second generation Optejet device

Announced the U.S. launch and commercial availability

of clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain following ocular surgery

Appointed Andrew Jones as Chief Financial Officer

Company to host conference call and webcast

today, November 12th, at 4:30 pm ET

NEW YORK-November 12, 2024-Eyenovia,

Inc. (NASDAQ: EYEN), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet

topical ophthalmic medication dispensing platform, today announced its financial and operating results for the third quarter ended September

Third Quarter 2024 and Recent Business Developments

Michael Rowe, Chief Executive Officer, commented,

"We achieved another significant commercial milestone during the third quarter with the U.S. launch of clobetasol, the first new

ocular steroid approved in over 15 years. Clobetasol perfectly complements our mydriasis product, Mydcombi, and allows us to further leverage

our sales force while adding significant value to eye doctors and surgeons. We also experienced accelerating sales momentum with Mydcombi,

now having reached 230 offices as of September 30th.

"We also took a meaningful step forward

in the development of our Gen-2 Optejet device with the commencement of manufacture of registration batches, with Mydcombi as our lead

product. We look forward to submitting for FDA approval of this advanced technology with Mydcombi in 2025, and a possible approval in

2026, if successful.

"Regarding MicroPine, which we are developing

for pediatric progressive myopia, we are preparing for an interim analysis of the Phase 3 CHAPERONE data this quarter that, if successful,

we expect will meaningfully accelerate its remaining development path. We also executed several co-development agreements to evaluate

novel therapeutics in our Optejet dispenser as potential treatments for dry eye disease. Together, these indications represent multi-billion-dollar

addressable markets in the U.S. alone."

"With two differentiated commercial products,

another in late Phase 3 development, multiple opportunities in dry eye, and the advanced Gen-2 Optejet technology platform, I believe

we are creating a foundation from which we can drive significant growth and value creation in the months and years to come," Mr.

Third Quarter 2024 Financial Review

For the third quarter of 2024, net loss was approximately

$7.9 million, or $0.11 per share, as compared to a net loss of $7.3 million, or $0.18 per share, for the third quarter of 2023.

Research and development expenses totaled approximately

$3.5 million for the third quarter of 2024, which was relatively consistent with $3.6 million reported for the third quarter of 2023.

For the third quarter of 2024, selling, general

and administrative expenses were approximately $3.7 million, compared to $2.9 million for the third quarter of 2023, an increase of approximately

27.3% reflecting the establishment of the Company's sales force in 2024.

Total operating expenses for the third quarter

of 2024 were approximately $7.2 million, compared to approximately $6.5 million for the third quarter of 2023. This represents an increase

of approximately 10.6%. The third quarter 2024 operating expense figure includes approximately $1.2 million of non-cash expenses.

As of September 30, 2024, the Company's

unrestricted cash and cash equivalents were approximately $7.2 million. Eyenovia continues to evaluate a range of options to secure long-term

Conference Call and Webcast

The conference call is scheduled to begin at 4:30

pm ET today, November 12th. Participants should dial 1-877-407-9039 (domestic) or 1-201-689-8470 (international), and reference conference

To access the Call me feature, which avoids

having to wait for an operator, click here.

A live webcast of the conference call will also

be available here and on the investor relations page of the Company's corporate website at www.eyenovia.com. After the

live webcast, the event will be archived on Eyenovia's website for one year.

PLEASE GO TO MYDCOMBI.COM FOR IMPORTANT

SAFETY INFORMATION for MYDCOMBI (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5%

PLEASE GO TO CLOBETASOLBID.COM

FOR IMPORTANT SAFETY INFORMATION for Clobetasol Proprionate Ophthalmic Suspension 0.05%

About Eyenovia, Inc.

Eyenovia, Inc. (NASDAQ:

EYEN) is an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical

ophthalmic medication dispensing platform. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use,

enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may combine

to produce better treatment options and outcomes for patients and providers. The company's pre-NDA candidate, MicroPine, is being

developed for pediatric progressive myopia, a global epidemic impacting hundreds of millions of children worldwide and representing a

multi-billion-dollar addressable market. The company's current commercial portfolio includes clobetasol propionate ophthalmic suspension,

0.05%, for post-surgical pain and inflammation, and Mydcombi for mydriasis. Eyenovia has also secured licensing and development agreements

for additional multi-billion-dollar indications where the Optejet may be advantageous, including dry eye. For more information, visit

The Eyenovia Corporate Information slide

deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking Statements

historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking

statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs,

expectations, strategies, predictions or any other statements relating to our future activities or other future events or

conditions, including statements regarding the plans, strategies and objectives of management, statements regarding future capital

requirements, and estimated market opportunities for our products, product candidates and platform technology. These statements are

based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These

statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict.

Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted

in the forward-looking statements. In addition, such statements could be affected by risks and uncertainties related to, among other

things: the availability of sufficient financial resources to continue clinical development and commercialization of our products;

risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment, timing, progress and

results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals

for our product candidates; the potential impacts of any disruptions on our supply chain, including the availability of sufficient

components and materials used in our products and product candidates; the potential advantages of our products, product candidates

and platform technology; the rate and degree of market acceptance and clinical utility of our products and product candidates; our

estimates regarding the potential market opportunity for our products and product candidates; reliance on third parties to develop

and commercialize our products and product candidates; the ability of us and our partners to timely develop, implement and maintain

manufacturing, commercialization and marketing capabilities and strategies for our products and product candidates; the risk of

defects in, or returns of, our products; intellectual property risks; changes in legal, regulatory and legislative environments in

the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; our

competitive position; and other risks described from time to time in the "Risk Factors" section of our filings with the

U.S. Securities and Exchange Commission, including those described in our Annual Report on Form 10-K as well as our Quarterly

Reports on Form 10-Q, and supplemented from time to time by our Current Reports on Form 8-K. Any forward-looking statements speak

only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not

undertake any obligation to update any forward-looking statements.

Chief Financial Officer

Eyenovia Investor Contact:

LifeSci Advisors, LLC

Eyenovia Media Contact: